New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results
Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...
New version of Merck's cancer drug faces possible patent battle, WSJ reports
Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, ...
Health Care Roundup: Market Talk
Find insight on Merck KGaA, Bayer, Jazz Pharmaceuticals and the use of AI in China’s healthcare sector in the latest Market ...
BioSpace9d
Merck’s Injectable Keytruda Plans Create Legal Dispute With Halozyme: WSJ
The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...
Merck (MRK) Battling to Protect Key Cancer Drug as Patent Row Heats Up
Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...
New version of Merck's Keytruda faces possible patent battle, WSJ reports
Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...
Reuters10d
New version of Merck's Keytruda faces possible patent battle, WSJ reports
March 5 (Reuters) - Merck's (MRK.N), opens new tab injected ... Halozyme Therapeutics (HALO.O), opens new tab, the Wall Street Journal reported on Wednesday, citing people familiar with the ...